BAX and ovarian carcinoma: The previous findings reported by Meng et al. n in vitro and in vivo studies observed that fisetin‐treated cells (ovarian cancer cell line SKOV3) markedly decreased the tumor volume, tumor mass, and Bcl‐2 levels and increased the Bax expressions in concentration‐dependent manner in athymic rude rat model (Meng et al., 2016).